These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 19585618)
1. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618 [TBL] [Abstract][Full Text] [Related]
2. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Diab DL; Yerian L; Schauer P; Kashyap SR; Lopez R; Hazen SL; Feldstein AE Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1249-54. PubMed ID: 18995215 [TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548 [TBL] [Abstract][Full Text] [Related]
4. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Tamimi TI; Elgouhari HM; Alkhouri N; Yerian LM; Berk MP; Lopez R; Schauer PR; Zein NN; Feldstein AE J Hepatol; 2011 Jun; 54(6):1224-9. PubMed ID: 21145805 [TBL] [Abstract][Full Text] [Related]
5. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507 [TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877 [TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. Cao W; Zhao C; Shen C; Wang Y PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749 [TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979 [TBL] [Abstract][Full Text] [Related]
9. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932 [TBL] [Abstract][Full Text] [Related]
10. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis. El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506 [TBL] [Abstract][Full Text] [Related]
12. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262 [TBL] [Abstract][Full Text] [Related]
13. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399 [TBL] [Abstract][Full Text] [Related]
14. A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease. Choi SJ; Yoon S; Kim KK; Kim D; Lee HE; Kim KG; Shin SK; Park IB; Kim SM; Lee DH Diabetes Metab J; 2024 Jul; 48(4):740-751. PubMed ID: 38311058 [TBL] [Abstract][Full Text] [Related]
15. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. Jazwinski AB; Thompson AJ; Clark PJ; Naggie S; Tillmann HL; Patel K J Viral Hepat; 2012 Apr; 19(4):278-82. PubMed ID: 22404726 [TBL] [Abstract][Full Text] [Related]
16. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390 [TBL] [Abstract][Full Text] [Related]
17. Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population. Hasegawa Y; Kim SR; Hatae T; Ohta M; Fujinami A; Sugimoto K; Kim KI; Imoto S; Tohyama M; Kim SK; Ikura Y; Kudo M Dig Dis; 2015 Oct; 33(6):715-20. PubMed ID: 26488474 [TBL] [Abstract][Full Text] [Related]
19. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Kim YS; Jung ES; Hur W; Bae SH; Choi JY; Song MJ; Kim CW; Jo SH; Lee CD; Lee YS; Choi SW; Yang JM; Jang JW; Kim SG; Jung SW; Kim HK; Chae HB; Yoon SK Clin Mol Hepatol; 2013 Jun; 19(2):120-30. PubMed ID: 23837136 [TBL] [Abstract][Full Text] [Related]
20. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Neuschwander-Tetri BA; Clark JM; Bass NM; Van Natta ML; Unalp-Arida A; Tonascia J; Zein CO; Brunt EM; Kleiner DE; McCullough AJ; Sanyal AJ; Diehl AM; Lavine JE; Chalasani N; Kowdley KV; Hepatology; 2010 Sep; 52(3):913-24. PubMed ID: 20648476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]